These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29939099)

  • 1. Combination effect of anti-rheumatic medications for coronary artery diseases risk in rheumatoid arthritis: a nationwide population-based cohort study.
    Hung YM; Lin L; Wang YH; Wei JC; Wang PY; Chiou JY
    Curr Med Res Opin; 2019 Feb; 35(2):313-320. PubMed ID: 29939099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study.
    Hung YM; Lin L; Chen CM; Chiou JY; Wang YH; Wang PY; Wei JC
    PLoS One; 2017; 12(6):e0179081. PubMed ID: 28658301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.
    Hung YM; Wang YH; Lin L; Wang PYP; Chiou JY; Wei JC
    Int J Clin Pract; 2018 May; 72(5):e13095. PubMed ID: 29691971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis.
    Bili A; Tang X; Pranesh S; Bozaite R; Morris SJ; Antohe JL; Kirchner HL; Wasko MC
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):355-63. PubMed ID: 24023053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
    Calgüneri M; Pay S; Calişkaner Z; Apraş S; Kiraz S; Ertenli I; Cobankara V
    Clin Exp Rheumatol; 1999; 17(6):699-704. PubMed ID: 10609068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.
    Maetzel A; Wong A; Strand V; Tugwell P; Wells G; Bombardier C
    Rheumatology (Oxford); 2000 Sep; 39(9):975-81. PubMed ID: 10986302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.
    Tam HW; Chen CM; Leong PY; Chen CH; Li YC; Wang YH; Lin LC; Chiou JY; Wei JC
    Int J Rheum Dis; 2018 Aug; 21(8):1591-1599. PubMed ID: 29372595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.
    Moura CS; Abrahamowicz M; Beauchamp ME; Lacaille D; Wang Y; Boire G; Fortin PR; Bessette L; Bombardier C; Widdifield J; Hanly JG; Feldman D; Maksymowych W; Peschken C; Barnabe C; Edworthy S; Bernatsky S;
    Arthritis Res Ther; 2015 Aug; 17(1):197. PubMed ID: 26235697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
    Mittal N; Mittal R; Sharma A; Jose V; Wanchu A; Singh S
    Singapore Med J; 2012 Aug; 53(8):532-6. PubMed ID: 22941131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs.
    Chester Wasko M; Dasgupta A; Ilse Sears G; Fries JF; Ward MM
    Arthritis Care Res (Hoboken); 2016 May; 68(5):706-10. PubMed ID: 26415107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.